ArticleCNS neuroscience & therapeutics2013
Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme.
Article in CNS neuroscience & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.BMC cancer · 2024Pooled it
- A Novel Cuproptosis-Related Gene Signature Predicts Prognosis in Papillary Thyroid Carcinoma Patients.Combinatorial chemistry & high throughput screening · 2025Article
- Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma.Journal of cellular and molecular medicine · 2024Article
- Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas.Diagnostics (Basel, Switzerland) · 2023Article
- A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.Journal of cancer research and clinical oncology · 2023Article
- Article
- A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.Frontiers in oncology · 2022Article
- MEOX2 Transcription Factor Is Involved in Survival and Adhesion of Glioma Stem-like Cells.Cancers · 2021Article
- Promoting Prognostic Model Application: A Review Based on Gliomas.Journal of oncology · 2021Review
- Prognostic significance of MEOX2 in gliomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.Cell death & disease · 2018Article
- Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.Medical oncology (Northwood, London, England) · 2017Article
- RNA processing as an alternative route to attack glioblastoma.Human genetics · 2017Review
- Evaluating the Prognostic Accuracy of Biomarkers for Glioblastoma Multiforme Using The Cancer Genome Atlas Data.Cancer informatics · 2017Review
- Joint Covariate Detection on Expression Profiles for Selecting Prognostic miRNAs in Glioblastoma.BioMed research international · 2017Article
- Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis.International journal of molecular medicine · 2016Article
- Article
- Microarray Analysis in Glioblastomas.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling.Oncotarget · 2015Article
- AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.CNS neuroscience & therapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Cancer Genome Atlas (TCGA) has divided patients with glioblastoma multiforme (GBM) into four subtypes based on mRNA expression microarray. The mesenchymal subtype, with a larger proportion, is considered a more lethal one. Clinical outcome prediction is required to better guide more personalized treatment for these patients.
aimsThe objective of this study was to identify a mRNA expression signature to improve outcome prediction for patients with mesenchymal GBM.
resultsFor signature identification and validation, we downloaded mRNA expression microarray data from TCGA as training set and data from Rembrandt and GSE16011 as validation set. Cox regression and risk-score analysis were used to develop the 4 signatures, which were function and prognosis associated as revealed by Gene Ontology (GO) analysis and Gene Set Variation Analysis (GSVA). Patients who had high-risk scores according to the signatures had poor overall survival compared with patients who had low-risk scores.
conclusionsThe signatures were identified as risk predictors that patients who had a high-risk score tended to have unfavorable outcome, demonstrating their potential for personalizing cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.